Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Other Operating Expenses (2016 - 2024)

PharmaCyte Biotech (PMCB) has disclosed Other Operating Expenses for 16 consecutive years, with -$601698.0 as the latest value for Q2 2025.

  • On a quarterly basis, Other Operating Expenses rose 48.16% to -$601698.0 in Q2 2025 year-over-year; TTM through Jan 2025 was -$559024.0, a 115.32% decrease, with the full-year FY2024 number at -$1.6 million, changed N/A from a year prior.
  • Other Operating Expenses was -$601698.0 for Q2 2025 at PharmaCyte Biotech, down from $601698.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.0 million in Q4 2022 to a low of -$1.2 million in Q2 2024.
  • A 5-year average of $660666.1 and a median of $606323.0 in 2021 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 220.42% in 2022, then plummeted 337.21% in 2024.
  • PharmaCyte Biotech's Other Operating Expenses stood at $610948.0 in 2021, then soared by 220.42% to $2.0 million in 2022, then crashed by 46.11% to $1.1 million in 2023, then crashed by 210.02% to -$1.2 million in 2024, then soared by 48.16% to -$601698.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Other Operating Expenses are -$601698.0 (Q2 2025), $601698.0 (Q1 2025), and -$1.2 million (Q2 2024).